乌司奴单抗生物类似药ABP 654治疗中重度斑块状银屑病的52周随机双盲对照研究
本研究为随机双盲活性对照单次转换比较临床研究(NCT04607980),在中重度斑块状银屑病患者中比较ABP 654与乌司奴单抗参照品的疗效、安全性和免疫原性。第12周PASI较基线改善百分比两组均为81.9,组间差异点估计0.14(90%CI -2.6至2.9),落在预设相似性界值(-10至10)内。第28周单次转换未影响52周研究剩余期间的疗效、安全性或免疫原性,支持两者无临床意义差异的结论。
要点
- ABP 654与乌司奴单抗参照品第12周PASI改善百分比均为81.9,差异0.14(90%CI -2.6至2.9)在相似性界值内。
- 研究全程两组次要疗效、安全性和免疫原性分析结果相似。
- 第28周由参照品单次转换至ABP 654对52周剩余期间结果无影响。
核心结论
- ABP 654与乌司奴单抗参照品在中重度斑块状银屑病患者中疗效、安全性和免疫原性临床相似。
- 第28周单次转换未影响52周研究剩余期间的疗效、安全性或免疫原性,支持两者无临床意义差异。
研究设计与样本
- 随机双盲活性对照单次转换比较临床研究(NCT04607980)。
- 患者按1:1随机接受ABP 654或乌司奴单抗参照品,按体重45 mg或90 mg皮下给药,第0、4、16周。
- 第28周PASI改善≥75%的患者再随机:ABP 654组继续ABP 654,参照品组再随机继续参照品或转换至ABP 654。
- 主要疗效终点为基线至第12周PASI改善百分比。
主要发现
- 第12周PASI较基线改善百分比(观察值均值±SD):ABP 654组81.9±19.9,乌司奴单抗参照品组81.9±19.6。
- 第12周PASI改善百分比组间均值差点估计0.14,双侧90%CI(-2.6至2.9),在预设相似性界值(-10至10)内。
- 研究全程次要疗效分析、安全性和免疫原性特征在各治疗组间相似。
关键数值与推荐
- 主要终点相似性界值为(-10至10)。
- 第28周PASI改善≥75%的患者进入再随机阶段。
临床怎么用
- ABP 654可作为乌司奴单抗参照品的生物类似药用于中重度斑块状银屑病。
- 由乌司奴单抗参照品单次转换至ABP 654在52周内未见疗效、安全性或免疫原性影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: ABP 654 is a biosimilar to ustekinumab reference product (RP). ABP 654 has been shown to have an amino acid sequence identical to ustekinumab RP and they are similar in structure, purity and potency, as well as clinical pharmacokinetics and safety in healthy volunteers. OBJECTIVES: To compare the efficacy, safety and immunogenicity of ABP 654 and ustekinumab RP in patients with moderate-to-severe plaque psoriasis in a randomized double-blinded active-controlled single-transition comparative clinical study (NCT04607980). METHODS: Patients were randomized 1 : 1 to receive ABP 654 or ustekinumab RP at a weight-based dose of 45 mg or 90 mg administered subcutaneously on day 1 (week 0), week 4 and week 16. At week 28, patients with a ≥ 75% improvement in Psoriasis Area and Severity Index (PASI) were re-randomized such that those initially randomized to ABP 654 continued to receive ABP 654 and those initially randomized to ustekinumab RP were re-randomized to either continue on ustekinumab RP or transition to ABP 654. The primary efficacy endpoint was percentage improvement in PASI from baseline to week 12. Secondary endpoints included additional efficacy measurements, as well as an assessment of adverse events and antidrug antibodies. RESULTS: At week 12, the observed mean (SD) percentage improvement in PASI from baseline was 81.9 (19.9) and 81.9 (19.6) for the ABP 654 and ustekinumab RP treatment groups, respectively. The point estimate of the mean difference in percentage PASI improvement from baseline to week 12 between the treatment groups was 0.14 with a two-sided 90% confidence interval (CI) of (-2.6 to 2.9), well within the prespecified similarity margin of (-10 to 10). In addition, throughout the study, secondary efficacy analyses and safety and immunogenicity profiles were similar across the treatment groups. CONCLUSIONS: These results indicate that ABP 654 and ustekinumab RP are clinically similar in efficacy, safety and immunogenicity in patients with moderate-to-severe plaque psoriasis. Further, a single transition from ustekinumab RP to ABP 654 at week 28 had no impact on the efficacy, safety or immunogenicity results for the remainder of the 52-week study, supporting a conclusion of no clinically meaningful differences between ABP 654 and ustekinumab RP. Stelara® (also known as ‘ustekinumab’) is a medicine used to treat people with psoriasis. Psoriasis is a common skin condition characterized by the formation of thick, silvery or red patches on the skin’s surface. These patches are called ‘plaques’ and appear on the elbows, knees, scalp, lower back and other areas on the body. Ustekinumab is a ‘biologic drug’. That means it is made from antibodies rather than from chemicals. Ustekinumab targets proteins that regulate the immune system and are involved in inflammation. By blocking these proteins, ustekinumab reduces inflammation and relieves the symptoms of psoriasis. Biosimilars are medications that are very similar to an approved biologic medication. Biosimilars should work the same way as the original (or ‘reference’) medication. One biosimilar to ustekinumab is called ‘ABP 654’. In this study, we looked at how effective and safe ABP 654 and ustekinumab are in people with moderate-to-severe psoriasis. We found that ABP 654 and ustekinumab were similar in how effective and safe they were in these patients. Our results suggest that there were no important differences between ustekinumab and ABP 654. Studies like this are required by regulatory authorities to ensure that biosimilars are as safe and work as well as their reference products.
引用
- Blauvelt A, Papp K, Trivedi M, et al. Efficacy and safety of the ustekinumab biosimilar ABP 654 in patients with moderate-to-severe plaque psoriasis: a randomized double-blinded active-controlled comparative clinical study over 52 weeks. Br J Dermatol. 2025. PMID: 39442018. doi:10.1093/bjd/ljae402
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。